Jordi Muntañola, new CEO of the Salvat Pharmaceutical Group
A new phase begins for the Salvat Pharmaceutical Group, comprised of Laboratorios Salvat, Pharmaloop, and Salvat USA. The pharmaceutical company has appointed Jordi Muntañola as the new Chief Executive Officer (CEO). With an international leadership profile and over 20 years of experience in the pharmaceutical industry, Muntañola takes on the role with the aim of consolidating the company’s global expansion and strengthening its presence in key markets.
Born in Barcelona in 1978, Muntañola holds a PhD in Molecular Biology from the University of Navarra and an MBA from ESADE. Throughout his career, he has worked at companies like Laboratorios Esteve, Grupo Werfen, and Esaote, leading teams in R&D, corporate strategy, operations, business development, and transformation office. Recently, he held the position of Chief Commercial Officer (CCO) for the global pharmaceutical activity at Laboratorios Esteve, where he led its international expansion by accelerating profitable growth, developing high-performance teams, and expanding presence in key markets such as Europe, the United States, and China. Additionally, Muntañola has extensive experience in M&A, noted for his work in business development.
Innovation and International Expansion as Strategic Pillars
Muntañola’s appointment is part of Salvat’s strategic plan to accelerate its global growth and continue its commitment to innovation in the pharmaceutical sector. “Salvat Group is a company with great potential, and it is an honor to lead the company in this new phase. Together, we will strengthen our global position and continue bringing innovation to our patients,” stated Muntañola.
Jordi Muntañola replaces Alberto Bueno, who concludes his tenure leading the company after 13 years. Under his direction, Salvat consolidated its growth and strengthened its production capacity, highlighting key projects such as the Pharmaloop plant, enabling Salvat to become the first Spanish laboratory authorized by the FDA to manufacture sterile drugs using BFS technology.